Azur Pharma in a broad range of transactions including:
its acquisition of the US rights to Gastrocrom from UCB Pharma
the acquisition of Pharmelle
the acquisition of FazaClo
an agreement with Elan to develop and commercialise once daily formulations of Clozapine (FazaClo)
the acquisition of Elestrin from BioSante Pharmaceuticals
the licensing of Niravam, Parcopa, Kemstro and Fluxid from UCB.
Alimentary Health Limited (a Cork-based biotech company with probiotic technology) in relation to a number of transactions, including:
a research development and cross-licensing agreement with Mead Johnson (which was then part of the BMS Group)
a research and development agreement with ConvaTec
a number of agreements with Procter & Gamble, including a gastrointestinal licensing agreement, a clinical studies evaluation agreement and a licensing agreement with P&G Pet Care.
Advised Elan Corporation plc on a broad range of matters, including a strategic alliance with Lilly, licensing transactions with Abbott Laboratories (single dose Tricor®/Crestor® combination) and Entremed (2ME2), and on the sub-license to AstraZeneca to develop and commercialise Unit Dose Budesonide, a fast-acting, reduced dose asthma treatment for children.
Acted for Forfas in relation to the review of the ICSTI National Code of Practice for Managing and Commercialising Intellectual Property from Public-Private Collaborative Research.
Fusion Nutraceuticals in relation to a license agreement with Alkem (India) for sucralose.
Merrion Pharmaceuticals on its US$58m license agreement with Novo Nordisk to develop and commercialise oral formulations on Novo Nordisk’s proprietary insulin analogues, using Merrion’s proprietary GIPET® technology.
Merrion Pharmaceuticals on its second US$58m license agreement with Novo Nordisk to develop and commercialise oral formulations of a Novo Nordisk proprietary GLP-1 Receptor Agonist, using Merrion’s proprietary technology and also an equity investment by Novo Nordisk in Merrion Pharmaceuticals.
National University of Ireland Galway in relation to a number of joint venture and licensing transactions including the licensing and joint venture with Eirzyme and the transaction between the Regenerative Medicine Institute at NUI Galway (Remedi) and Smith & Nephew.
Ovagen in relation to its corporate and life science legal requirements.
Royal College of Surgeons in Ireland in relation to a number of research collaborations, joint venture and licensing transactions.
Shupon International in relation to the in-licensing of its proprietary technology with broad application for the beverage sector.
A number of medical device companies in relation to distribution and licensing agreements with a number of US partners.
A number of spin-out companies in relation to strategic licensing transactions with US biotech companies, including a worldwide licensing agreement between Diabetica Limited and Amylin Pharmaceuticals in relation to Diabetica’s Intellectual Property for the development of GIP Agonists.
A number of Irish food companies in relation to joint venture and licensing arrangements, including agreements with US not for profit organisations.
.jpg?n=5702 "ByrneWallace Logo")
